Consistent with our hypothesis, the Aspiletreins bound to the targets with high affinity and likely inhibited the tumor-promoting functions of STAT3, VEGFA, HSP90AA1, and FGF2 or enhanced tumor-suppressing activity of IL2, or both. The gene discussed is STAT3; the disease is neoplasm.